ArticleTherapeutic advances in hematology2025
Efficacy of therapeutic strategies on thrombocytopenia after hematopoietic stem cell transplantation-an evidence-based meta-analysis.
Article in Therapeutic advances in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thrombocytopenia is a common complication following hematopoietic stem cell transplantation, and there is currently no standardized therapeutic approach for its management. Objectives: This article aims to systematically review the existing clinical treatment regimens for this condition and assess their efficacy. Design: This is a systematic review and meta-analysis. Data sources and methods: We conducted a comprehensive literature search in several databases, including PubMed, Web of Science, Cochrane Library, and Embase, up until October 30, 2024. A total of 43 datasets involving 1154 patients were included for further analysis. Therapeutic effectiveness was defined as a patient's platelet count being above 20 × 10 Results: Our study included a total of 42 articles. The results of our study show that Decitabine and Romiplostim show relatively high effectiveness in treating thrombocytopenia after hematopoietic stem cell transplantation (HSCT), with efficacy rates of 83% (95% CI: 57%-99%) and 87% (95% CI: 69%-98%), respectively. Eltrombopag and Avatrombopag also demonstrated good efficacy, with overall utilities of 68% and 73%. Subgroup analyses revealed that Eltrombopag was particularly effective in adolescent patients compared to adults. Most of the reported side effects were well tolerated, with an overall effect value of 14% (95% CI: 11%-18%, Conclusion: Our meta-analysis suggests a significant efficacy of both Romiplostim and Decitabine in the treatment for thrombocytopenia after HSCT, while Eltrombopag showed significantly better efficacy in the pediatric subgroup compared to elder patients, and the side effects of the drugs are within acceptable range.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.